astrazeneca glp 1 AstraZeneca’s experimental obesity pill helped patients lose up to 11.8% of their body weight in a mid-stage trial, as competition intensifies in the rapidly growing market for oral weight-loss drugs. Type 2 Diabetes: AstraZeneca's New

The new coverage could unlock millions of potential patients for Novo and Lilly, intensifying their competition in the obesity market

With 2024 as the year when the AOM market took shape, and 2026 a pivotal year that will define future competitive dynamics as the next wave of AOMs launch, and when the first off patent semaglutide likely becomes available in some countries, it is easy to dismiss 2025 as an uneventful transition

Petrelintide, developed by Zealand Pharma, is a once-weekly, long-acting analog structurally similar to cagrilintide and is being evaluated in a phase 2 trial (ZUPREME-1) for obesity treatment

Read our recent blog post written by Dara Katcher Levy and Sarah Wicks where they provide some high level thoughts on the CDER ad/pro letters released yesterday

3638 Start with screening Because patients being considered for GLP-1 receptor agonist therapy are already at risk of developing acute pancreatitis due to having type 2 diabetes, obesity or both, screening for other potential risk factors before starting treatment is recommended